Correlation between inteferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells

Journal of General Virology

Volumn 86, Issue 5, 2005, Pages 1489-1497

  Rudd, Penny ^a   Lemay, Guy ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PROTEIN KINASE R; RAS PROTEIN; ANTIVIRUS AGENT;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CHEMICAL MUTAGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME INDUCTION; HOST CELL; INHIBITION KINETICS; MAMMAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; R FACTOR; REOVIRUS; TUMOR CELL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS REPLICATION; ANIMAL; CELL CULTURE; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; MUTAGENESIS; ORTHOREOVIRUS; PHYSIOLOGY;

MAMMALIA; ORTHOREOVIRUS; REOVIRUS SP.;

ANIMALS; ANTIVIRAL AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; INTERFERONS; MICE; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS; ORTHOREOVIRUS, MAMMALIAN;

EID: 18144387525     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80628-0     Document Type: Article

References (57)

1. Alain, T., Hirasawa, K., Pon, K. J. & 9 other authors (2002). Reovirus therapy of lymphoid malignancies. Blood 100, 4146-4153.
2. Balachandran, S. & Barber, G. N. (2004). Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5, 51-65.
3. Bell, J. C., Garson, K. A., Lichty, B. D. & Stojdl, D. F. (2002). Oncolytic viruses: programmable tumour hunters. Curr Gene Ther 2, 243-254.
4. Bergeron, J., Mabrouk, T., Garzon, S. & Lemay, G. (1998). Characterization of the thermosensitive ts453 reovirus mutant: increased dsRNA binding of σ3 protein correlates with interferon resistance. Virology 246, 199-210.
5. Chiocca, E. A. (2002). Oncolytic viruses. Nat Rev Cancer 2, 938-950.
6. Clemens, M. J. & Elia, A. (1997). The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 17, 503-524.
7. Coffey, M. C., Strong, J. E., Forsyth, P. A. & Lee, P. W. (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334.
8. Danis, C. & Lemay, G. (1993). Protein synthesis in different cell lines infected with orthoreovirus serotype 3: inhibition of host-cell protein synthesis correlates with accelerated viral multiplication and cell killing. Biochem Cell Biol 71, 81-85.
9. Danis, C., Mabrouk, T., Faure, M. & Lemay, G. (1997). Interferon has no protective effect during acute or persistent reovirus infection of mouse SC1 fibroblasts. Virus Res 51, 139-149.
10. Denzler, K. L. & Jacobs, B. L. (1994). Site-directed mutagenic analysis of reovirus σ3 protein binding to dsRNA. Virology 204, 190-199.
11. Duncan, M. R., Stanish, S. M. & Cox, D. C. (1978). Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28, 444-449.
12. Etoh, T., Himeno, Y., Matsumoto, T., Aramaki, M., Kawano, K., Nishizono, A. & Kitano, S. (2003). Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 9, 1218-1223.
13. Fields, B. N. & Joklik, W. K. (1969). Isolation and preliminary genetic and biochemical characterization of temperature-sensitive mutants of reovirus. Virology 37, 335-342.
14. Gale, M. Jr & Katze, M. G. (1998). Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther 78, 29-46.
15. Gupta, S. L., Holmes, S. L. & Mehra, L. L. (1982). Interferon action against reovirus: activation of interferon-induced protein kinase in mouse L929 cells upon reovirus infection. Virology 120, 495-499.
16. Hashiro, G., Loh, P. C. & Yau, J. T. (1977). The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54, 307-315.
17. Hirasawa, K., Nishikawa, S. G., Norman, K. L., Alain, T., Kossakowska, A. & Lee, P. W. (2002). Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62, 1696-1701.
18. Hirasawa, K., Nishikawa, S. G., Norman, K. L., Coffey, M. C., Thompson, B. G., Yoon, C. S., Weisman, D. M. & Lee, P. W. (2003). Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63, 348-353.
19. Huismans, H. & Joklik, W. K. (1976). Reovirus-coded polypeptides in infected cells: isolation of two native monomeric polypeptides with affinity for single-stranded and double-stranded RNA, respectively. Virology 70, 411-424.
20. Ikegami, N. & Gomatos, P. J. (1968). Temperature-sensitive conditional-lethal mutants of reovirus 3. I. Isolation and characterization. Virology 36, 447-458.
21. Imani, F. & Jacobs, B. L. (1988). Inhibitory activity for the interferon-induced protein kinase is associated with the reovirus serotype 1 σ3 protein. Proc Natl Acad Sci U S A 85, 7887-7891.
22. Jacobs, B. L. & Ferguson, R. E. (1991). The Lang strain of reovirus serotype 1 and the Dearing strain of reovirus serotype 3 differ in their sensitivities to beta interferon. J Virol 65, 5102-5104.
23. Jacobs, B. L. & Langland, J. O. (1998). Reovirus sigma 3 protein: dsRNA binding and inhibition of RNA-activated protein kinase. Curr Top Microbiol Immunol 233, 185-196.
24. Katze, M. G. (1993). Games viruses play: a strategic initiative against the interferon-induced dsRNA-activated 68,000 Mr protein kinase. Semin Virol 4, 259-268.
25. Katze, M. G. (1995). Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol 3, 75-78.
26. Kilani, R. T., Tamimi, Y., Hanel, E. G., Wong, K. K., Karmali, S., Lee, P. W. & Moore, R. B. (2003). Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Res 93, 1-12.
27. Koleske, A. J., Baltimore, D. & Lisanti, M. P. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci U S A 92, 1381-1385.
28. Liemann, S., Chandran, K., Baker, T. S., Nibert, M. L. & Harrison, S. C. (2002). Structure of the reovirus membrane-penetration protein, μ1, in a complex with its protector protein, σ3. Cell 108, 283-295.
29. Lloyd, R. M. & Shatkin, A. J. (1992). Translational stimulation by reovirus polypeptide σ3: substitution for VAI RNA and inhibition of phosphorylation of the α subunit of eukaryotic initiation factor 2. J Virol 66, 6878-6884.
30. Mabrouk, T., Danis, C. & Lemay, G. (1995). Two basic motifs of reovirus sigma 3 protein are involved in double-stranded RNA binding. Biochem Cell Biol 73, 137-145.
31. Miller, F. E. & Samuel, C. E. (1992). Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: identification of a repeated basic amino acid motif within the C-terminal binding region. J Virol 66, 5347-5356.
32. Miyamoto, N. G. & Samuel, C. E. (1980). Mechanism of interferon action. Interferon-mediated inhibition of reovirus mRNA translation in the absence of detectable mRNA degradation but in the presence of protein phosphorylation. Virology 107, 461-475.
33. Mullen, J. T. & Tanabe, K. K. (2002). Viral oncolysis. Oncologist 7, 106-119.
34. Mundschau, L. J. & Faller, D. V. (1992). Oncogenic Ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2α-kinase activation. J Biol Chem 267, 23092-23098.
35. Mundschau, L. J. & Faller, D. V. (1994). Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 76, 792-800.
36. Nilsen, T. W., Maroney, P. A. & Baglioni, C. (1982). Inhibition of protein synthesis in reovirus-infected HeLa cells with elevated levels of interferon-induced protein kinase activity. J Biol Chem 257, 14593-14596.
37. Norman, K. L. & Lee, P. W. (2000). Reovirus as a novel oncolytic agent. J Clin Invest 105, 1035-1038.
38. Norman, K. L., Coffey, M. C., Hirasawa, K., Demetrick, D. J., Nishikawa, S. G., DiFrancesco, L. M., Strong, J. E. & Lee, P. W. (2002). Reovirus oncolysis of human breast cancer. Hum Gene Ther 13, 641-652.
39. Norman, K. L., Hirasawa, K., Yang, A.-D., Shields, M. A. & Lee, P. W. K. (2004). Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A 101, 11099-11104.
40. Olland, A. M., Jane-Valbuena, J., Schiff, L. A., Nibert, M. L. & Harrison, S. C. (2001). Structure of the reovirus outer capsid and dsRNA-binding protein σ3 at 1.8 Å resolution. EMBO J 20, 979-989.
41. Patrick, M., Duncan, R. & Coombs, K. M. (2001). Generation and genetic characterization of avian reovirus temperature-sensitive mutants. Virology 284, 113-122.
42. Proud, C. G. (1992). Protein phosphorylation in translational control. Curr Top Cell Regul 32, 243-369.
43. Samuel, C. E. (1998). Reoviruses and the interferon system. Curr Top Microbiol Immunol 233, 125-145.
44. Samuel, C. E., Kuhen, K. L., George, C. X., Ortega, L. G., Rende-Fournier, R. & Tanaka, H. (1997). The PKR protein kinase - an interferon-inducible regulator of cell growth and differentiation. Int J Hematol 65, 227-237.
45. Schiff, L. A. (1998). Reovirus capsid proteins sigma 3 and mu 1: interactions that influence viral entry, assembly, and translational control. Curr Top Microbiol Immunol 233, 167-183.
46. Schmechel, S., Chute, M., Skinner, P., Anderson, R. & Schiff, L. (1997). Preferential translation of reovirus mRNA by a σ3-dependent mechanism. Virology 232, 62-73.
47. Sherry, B., Torres, J. & Blum, M. A. (1998). Reovirus induction of and sensitivity to beta interferon in cardiac myocyte cultures correlate with induction of myocarditis and are determined by viral core proteins. J Virol 72, 1314-1323.
48. Strong, J. E. & Lee, P. W. (1996). The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70, 612-616.
49. Strong, J. E., Coffey, M. C., Tang, D., Sabinin, P. & Lee, P. W. (1998). The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17, 3351-3362.
50. Thirukkumaran, C. M., Luider, J. M., Stewart, D. A., Cheng, T., Lupichuk, S. M., Nodwell, M. J., Russell, J. A., Auer, I. A. & Morris, D. G. (2003). Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 102, 377-387.
51. Virgin, H. W. I., Tyler, K. L. & Dermody, T. S. (1996). Reovirus. In Viral Pathogenesis. Edited by N. Nathanson. Philadelphia: Lippincott-Raven Press.
52. Wang, Q., Bergeron, J., Mabrouk, T. & Lemay, G. (1996). Site-directed mutagenesis of the double-stranded RNA binding domain of bacterially-expressed σ3 reovirus protein. Virus Res 41, 141-151.
53. Wiebe, M. E. & Joklik, T. W. (1975). The mechanism of inhibition of reovirus replication by interferon. Virology 66, 229-240.
54. Wilcox, M. E., Yang, W., Senger, D. & 8 other authors (2001). Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93, 903-912.
55. Wildner, O. (2001). Oncolytic viruses as therapeutic agents. Ann Med 33, 291-304.
56. Yang, W. Q., Senger, D., Muzik, H. & 11 other authors (2003). Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 63, 3162-3172.
57. Yue, Z. & Shatkin, A. J. (1997). Double-stranded RNA-dependent protein kinase (PKR) is regulated by reovirus structural proteins. Virology 234, 364-371.